A major new study in the UK has shown that combining whole-genome sequencing (WGS) and real-world clinical data at a national scale can help deliver tailored, personalised
Patient support programmes (PSPs) hold great promise for oncology patients, healthcare professionals, and pharma companies by bridging the gap between clinic and home care.